McKesson Corp (MCK) stock analysis and fair value
MCK · NYSE · Healthcare
1021,54 US$
▲ +1,10%
Cerne score
71out of 100
Good
- Quality47
- Growth92
- Financial strength94
- Valuation54
- Dividends77
In 30 seconds
The business. Healthcare. Sells 403,4 B US$ a year, keeps 1% as profit and sales grow 11,1% a year (last 5 years).
Strength. Passes 6 of 8 quality checks and could repay its debt with 1,0 years of profit.
MCK fair value
Work out what the stock is worth with your own growth, margin and return assumptions. Free during launch.
See the fair valueMcKesson Corp key numbers
- Market cap
- 119,6 B US$
- P/E (price ÷ earnings)
- 26,6
- Dividend yield
- 0,31%
- Revenue growth
- 8,2%
- a year, over 9 years
- Profit margin
- 1,2%
- Quality checks
- 6/8
Fiscal 2026 financials, as filed with the SEC.
What analysts say
Buy
18 of 23 analysts recommend buying.
See everything about MCK on Cerne
- Fair value with your own assumptions
- Every analyst and price target
- 10 years of financials in simple charts
- Dividends, earnings and ratios vs. the sector